Xenetic Biosciences Extends Research Collaboration with Scripps Research to Advance DNase Platform
Xenetic Biosciences Inc. has extended its research collaboration with The Scripps Research Institute and Dr. Alexey Stepanov’s laboratory for an additional four months starting November 1, 2025. The focus is on advancing Xenetic’s DNase I platform in combination with CAR T-cell therapies, aiming to improve responses to CAR-T cell therapy for hematologic and solid tumors. Preclinical studies have shown promising results, and the program is moving toward Phase 1 clinical development.
Xenetic Biosciences Inc. has extended its research and development collaboration with The Scripps Research Institute and Dr. Alexey Stepanov’s laboratory. The partnership will continue for an additional four months starting November 1, 2025, focusing on advancing Xenetic’s DNase I platform in combination with CAR T-cell therapies. The collaboration aims to further evaluate the therapeutic potential of systemic DNase I, particularly in improving responses to CAR-T cell therapy for both hematologic and solid tumors. Preclinical studies have shown promising results, and the program is being advanced toward Phase 1 clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1103941) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
